Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lured By Rising Transplant Cases, Astellas Finally Brings Prograf To India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Japan's second-largest drug maker Astellas is bringing into India its flagship organ transplant drug Prograf (tacrolimus) in a bid to tap the Asian giant's steadily growing domestic pharmaceutical market. The product registration application for Prograf is pending with the Drug Controller General of India and Astellas hopes to launch the drug by the end of the current financial year

Related Content

UsernamePublicRestriction

Register

SC072014

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel